Daiichi, Apotex Settle Patent Suit Over Evoxac ANDA

Law360, New York (August 5, 2010, 2:44 PM EDT) -- Daiichi Sankyo Inc. has announced a settlement and licensing agreement in a patent infringement suit against Apotex Corp. that will allow the generic-drug maker to introduce its own version of Evoxac in 2012.

The agreement, revealed Wednesday, resolves the parties' dispute in the U.S. District Court for the District of Delaware, where Daiichi sued Apotex in June 2009 after the defendant sought regulatory approval for a generic form of the drug.

Under the agreement, Apotex has taken a license to U.S. Patent Number 5,340,821 that will...
To view the full article, register now.